Latest news with #Tixel
Yahoo
5 days ago
- Business
- Yahoo
Tixel i® Demonstrates Sustained Improvements in Dry Eye Symptoms
Recent Publication Reports Durable Results and Patient Satisfaction KNOXVILLE, Tenn., June 3, 2025 /PRNewswire/ -- A new article in JOJ Ophthalmology confirms Tixel i® provides sustained, strong clinical outcomes for patients with Evaporative Dry Eye Disease (DED) caused by Meibomian Gland Dysfunction (MGD). This FDA-cleared, non-invasive device uses patented Thermo-Mechanical Action® (TMA®) to deliver durable improvements in key indicators, including patient satisfaction and clinical results. Key Highlights Tear Break-Up Time (TBUT): Improved significantly from 4.0 ± 1.5 seconds to 9.2 ± 4.0 seconds, reaching a normal physiological range. Meibomian Gland Score (MGS): Increased by over 17 points, comparable to or exceeding thermal pulsation systems. Ocular Surface Disease Index (OSDI): Scores dropped by over 21 points, reflecting reduced symptoms and significantly improved quality of life. Safety: No device-related adverse effects were recorded. Real World Experience Confirms Study Results One 76-year-old patient with severe dry eye, unable to tolerate traditional treatments like IPL, found significant relief with Tixel i. Dr. Lauren Bailey of West Plano Dry Eye and Aesthetics noted, "It's quick, easy, and finally gave us a way forward after hitting so many walls. Tixel i is perfect for our low vision patients." Dr. Bailey also treated a 53-year-old patient with a two-year history of severe dry eye that required eye drops four to six times daily. Following a treatment plan that included three sessions of Tixel i, the patient reported noticeable improvement in discomfort and a substantial reduction in the impact of dry eye on daily activities. By the four-week follow-up, her clinical severity had improved from severe to moderate, drop usage had decreased, and objective metrics showed dramatic improvement: TBUT increased from 0 to 8 seconds and MGSS improved from 2 to 40 (OD) and 39 (OS), leading to reduced eye drop usage and improved daily activities. For more information, fill out this form: About Novoxel® Established in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit Novoxel, Tixel, and Thermo-Mechanical Action (TMA) are registered trademarks of Novoxel Ltd. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
5 days ago
- Business
- Associated Press
Leading New York Ophthalmologist Integrates Tixel® into Dry Eye Treatments
WATERTOWN, N.Y., June 3, 2025 /PRNewswire/ -- Dr. Noaman Sanni, a leading ophthalmologist and CEO of Center for Sight New York, has witnessed significant patient and revenue growth after adding Tixel i into his practice. Tixel i, Novoxel's FDA-cleared device, utilizes patented Thermo-Mechanical Action® (TMA) to effectively treat Meibomian Gland Dysfunction (MGD) – a common cause of dry eye – in under two minutes. Within just two months, Dr. Sanni's team treated over 225 patients, making Tixel i a truly transformative addition to their dry eye protocols. Dr. Sanni noted, 'We were not really focused on the business aspect, because we were focusing on the medical aspect and helping our patients. Therefore, I was surprised at the positive financial impact due to rapid patient acceptance.' CLINICALLY PROVEN RESULTS - Tixel i isn't just praised by patients; it's backed by strong clinical data. A pivotal trial showed remarkable improvements: PHYSICIAN ENDORSEMENT - Dr. Debra Koloms, Medical Director at Center for Sight New York, personally experienced Tixel i treatment for her own dry eye. 'After 2 Tixel i treatments, I no longer need punctal plugs or drops,' she shared. After personally treating over 50 patients in six weeks, Dr. Koloms declared, 'In 40 years of practice, this is the most impressive treatment I've ever seen for Meibomian Gland Dysfunction.' Center for Sight New York offers consultations and Tixel i treatment previews for those interested in learning more about this innovative dry eye solution. Novoxel, Tixel, Thermo-Mechanical Action, and TMA are registered trademarks of Novoxel LTD. ABOUT NOVOXEL Established in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit ABOUT CENTER FOR SIGHT Established in the 1940s, Center for Sight New York is one of Northern New York's largest and most respected eye care practices, with locations in Watertown and Ogdensburg. Under the leadership of Dr. Noaman Sanni since 1995, the practice boasts a team of board-certified ophthalmologists and skilled technicians. They provide state-of-the-art diagnostics and advanced treatments with a patient-centered approach, aiming to improve quality of life through exceptional vision solutions. View original content to download multimedia: SOURCE Novoxel Inc.
Yahoo
5 days ago
- Business
- Yahoo
Leading New York Ophthalmologist Integrates Tixel® into Dry Eye Treatments
WATERTOWN, N.Y., June 3, 2025 /PRNewswire/ -- Dr. Noaman Sanni, a leading ophthalmologist and CEO of Center for Sight New York, has witnessed significant patient and revenue growth after adding Tixel i into his practice. Tixel i, Novoxel's FDA-cleared device, utilizes patented Thermo-Mechanical Action® (TMA) to effectively treat Meibomian Gland Dysfunction (MGD) – a common cause of dry eye – in under two minutes. Within just two months, Dr. Sanni's team treated over 225 patients, making Tixel i a truly transformative addition to their dry eye protocols. Dr. Sanni noted, "We were not really focused on the business aspect, because we were focusing on the medical aspect and helping our patients. Therefore, I was surprised at the positive financial impact due to rapid patient acceptance." CLINICALLY PROVEN RESULTS - Tixel i isn't just praised by patients; it's backed by strong clinical data. A pivotal trial showed remarkable improvements: Tear Break-Up Time (TBUT) improved from severe to normal physiological range and sustained for 6 months. Meibomian Gland Score (MGS) increased by over 17 points, comparable to or exceeding thermal pulsation systems. Ocular Surface Disease Index (OSDI) scores dropped by more than 21 points, indicating a significant improvement in patients' quality of life. Crucially, no adverse device-related effects were reported. PHYSICIAN ENDORSEMENT - Dr. Debra Koloms, Medical Director at Center for Sight New York, personally experienced Tixel i treatment for her own dry eye. "After 2 Tixel i treatments, I no longer need punctal plugs or drops," she shared. After personally treating over 50 patients in six weeks, Dr. Koloms declared, "In 40 years of practice, this is the most impressive treatment I've ever seen for Meibomian Gland Dysfunction." Center for Sight New York offers consultations and Tixel i treatment previews for those interested in learning more about this innovative dry eye solution. Novoxel, Tixel, Thermo-Mechanical Action, and TMA are registered trademarks of Novoxel LTD. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation, holding numerous patents worldwide. Their Tixel family of products utilize proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results. These treatments are non-invasive, radiation-free, require minimal downtime, and involve no expensive single-use cartridges, bleeding, or significant pain. To learn more, visit ABOUT CENTER FOR SIGHTEstablished in the 1940s, Center for Sight New York is one of Northern New York's largest and most respected eye care practices, with locations in Watertown and Ogdensburg. Under the leadership of Dr. Noaman Sanni since 1995, the practice boasts a team of board-certified ophthalmologists and skilled technicians. They provide state-of-the-art diagnostics and advanced treatments with a patient-centered approach, aiming to improve quality of life through exceptional vision solutions. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-06-2025
- Business
- Yahoo
Novoxel Inc. and GPOphtho Finalize Strategic Agreement to Deliver Breakthrough Dry Eye Treatments and Aesthetic Procedures to Eyecare Physicians Nationwide
KNOXVILLE, Tenn., May 31, 2025 /PRNewswire/ -- Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel's innovative Tixel® device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to eyecare physicians nationwide. Expanding Access to Advanced Dry Eye and Aesthetic Solutions The agreement grants GPOphtho's network of ophthalmologists and optometrists discounted pricing and value-added packages for Novoxel's Tixel devices. Tixel i® is specifically designed to treat Meibomian Gland Dysfunction (MGD), offering a fast and targeted solution for both upper and lower eyelids. A recent clinical trial (Sanni, et al, 2025) concluded that Tixel i is a safe, non-pharmacologic, first-line treatment for MGD. "What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. The FDA-cleared family of products provide year-round treatments for all skin types and age groups. They offer non-invasive rejuvenation without needles, bleeding, or pain, minimal downtime, no expensive consumables, and are radiation-free. Empowering Eyecare Physicians with New Revenue Streams "Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. This agreement will enable eyecare professionals to easily integrate both functional and cosmetic procedures, creating new revenue streams and enhancing patient satisfaction. Both Novoxel and GPOphtho are committed to bringing innovative, cutting-edge technology to more patients and practices across the US. For product demos or pricing information, visit Existing GPOphtho members can inquire about adding Tixel through their GPOphtho contact. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation. Novoxel has been granted numerous patents around the world. The company's Tixel family of products use proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results even though treatments are non-invasive. There is minimal downtime, no expensive single-use cartridges, no bleeding, and minimal/no pain. Because the affordable treatments are radiation-free, safety eyewear is not required for clinicians. Visit for more information. ABOUT GPOPHTHOGPOphtho's mission is to save our members time and money for all of their business needs by becoming the most comprehensive ophthalmic group purchasing organization. By leveraging collective buying power, GPOphtho is able to negotiate discounted rates and value-added packages for a diverse range of products and services, allowing physicians and their staff to focus on providing the best care for their patients. Plus, members can take advantage of all GPOphtho's negotiated contracts without paying administrative fees. For more information, visit Interested eyecare physicians can join GPOphtho at no cost. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-06-2025
- Business
- Yahoo
Novoxel Inc. and GPOphtho Finalize Strategic Agreement to Deliver Breakthrough Dry Eye Treatments and Aesthetic Procedures to Eyecare Physicians Nationwide
KNOXVILLE, Tenn., May 31, 2025 /PRNewswire/ -- Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel's innovative Tixel® device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to eyecare physicians nationwide. Expanding Access to Advanced Dry Eye and Aesthetic Solutions The agreement grants GPOphtho's network of ophthalmologists and optometrists discounted pricing and value-added packages for Novoxel's Tixel devices. Tixel i® is specifically designed to treat Meibomian Gland Dysfunction (MGD), offering a fast and targeted solution for both upper and lower eyelids. A recent clinical trial (Sanni, et al, 2025) concluded that Tixel i is a safe, non-pharmacologic, first-line treatment for MGD. "What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. The FDA-cleared family of products provide year-round treatments for all skin types and age groups. They offer non-invasive rejuvenation without needles, bleeding, or pain, minimal downtime, no expensive consumables, and are radiation-free. Empowering Eyecare Physicians with New Revenue Streams "Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology," says Cynthia Matossian, MD, FACS, and CEO of GPOphtho. This agreement will enable eyecare professionals to easily integrate both functional and cosmetic procedures, creating new revenue streams and enhancing patient satisfaction. Both Novoxel and GPOphtho are committed to bringing innovative, cutting-edge technology to more patients and practices across the US. For product demos or pricing information, visit Existing GPOphtho members can inquire about adding Tixel through their GPOphtho contact. ABOUT NOVOXELEstablished in 2011, Novoxel Ltd. focuses on scientific and clinical innovation. Novoxel has been granted numerous patents around the world. The company's Tixel family of products use proprietary Thermo-Mechanical Action (TMA®) to deliver noticeable clinical results even though treatments are non-invasive. There is minimal downtime, no expensive single-use cartridges, no bleeding, and minimal/no pain. Because the affordable treatments are radiation-free, safety eyewear is not required for clinicians. Visit for more information. ABOUT GPOPHTHOGPOphtho's mission is to save our members time and money for all of their business needs by becoming the most comprehensive ophthalmic group purchasing organization. By leveraging collective buying power, GPOphtho is able to negotiate discounted rates and value-added packages for a diverse range of products and services, allowing physicians and their staff to focus on providing the best care for their patients. Plus, members can take advantage of all GPOphtho's negotiated contracts without paying administrative fees. For more information, visit Interested eyecare physicians can join GPOphtho at no cost. View original content to download multimedia: SOURCE Novoxel Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
